Login to Your Account



Many Trials, Many Tribulations

Anti-CD20 Drugs: Magic Bullet In Treating 'Enigmatic' Lupus?

By Randall Osborne


Monday, November 5, 2007
Genelabs Technologies Inc.'s $23.7 million financing at the start of October sparked renewed interest in its Phase III drug Prestara for lupus - and in the indication itself, for which a new therapy based on randomized, placebo-controlled trials has not been approved in more than four decades. (BioWorld Financial Watch)

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription